JP2008507368A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008507368A5 JP2008507368A5 JP2007522850A JP2007522850A JP2008507368A5 JP 2008507368 A5 JP2008507368 A5 JP 2008507368A5 JP 2007522850 A JP2007522850 A JP 2007522850A JP 2007522850 A JP2007522850 A JP 2007522850A JP 2008507368 A5 JP2008507368 A5 JP 2008507368A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- subject
- change
- alkyl
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000008859 change Effects 0.000 claims 33
- 238000000034 method Methods 0.000 claims 33
- 125000000217 alkyl group Chemical group 0.000 claims 28
- 230000004199 lung function Effects 0.000 claims 26
- 239000008194 pharmaceutical composition Substances 0.000 claims 25
- 150000001875 compounds Chemical class 0.000 claims 22
- 125000003118 aryl group Chemical group 0.000 claims 20
- 229910052739 hydrogen Inorganic materials 0.000 claims 20
- 239000001257 hydrogen Substances 0.000 claims 20
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 16
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims 16
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 16
- 125000000623 heterocyclic group Chemical group 0.000 claims 16
- 150000002431 hydrogen Chemical class 0.000 claims 16
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 16
- 208000024891 symptom Diseases 0.000 claims 15
- 208000011623 Obstructive Lung disease Diseases 0.000 claims 14
- 125000003545 alkoxy group Chemical group 0.000 claims 12
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 12
- -1 carboxy, hydroxy Chemical group 0.000 claims 12
- 125000004438 haloalkoxy group Chemical group 0.000 claims 12
- 125000001188 haloalkyl group Chemical group 0.000 claims 12
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 11
- 208000006673 asthma Diseases 0.000 claims 9
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 claims 8
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims 8
- 229960001456 adenosine triphosphate Drugs 0.000 claims 8
- 125000003342 alkenyl group Chemical group 0.000 claims 8
- 125000004450 alkenylene group Chemical group 0.000 claims 8
- 125000002947 alkylene group Chemical group 0.000 claims 8
- 125000000304 alkynyl group Chemical group 0.000 claims 8
- 125000004419 alkynylene group Chemical group 0.000 claims 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 125000003831 tetrazolyl group Chemical group 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- 229940124597 therapeutic agent Drugs 0.000 claims 6
- 230000002685 pulmonary effect Effects 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 230000001939 inductive effect Effects 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 210000004126 nerve fiber Anatomy 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 230000001953 sensory effect Effects 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000004434 sulfur atom Chemical group 0.000 claims 4
- VQGBOYBIENNKMI-LJAQVGFWSA-N 5-[(3-phenoxyphenyl)methyl-[(1s)-1,2,3,4-tetrahydronaphthalen-1-yl]carbamoyl]benzene-1,2,4-tricarboxylic acid Chemical compound C1=C(C(O)=O)C(C(=O)O)=CC(C(O)=O)=C1C(=O)N([C@@H]1C2=CC=CC=C2CCC1)CC1=CC=CC(OC=2C=CC=CC=2)=C1 VQGBOYBIENNKMI-LJAQVGFWSA-N 0.000 claims 3
- 206010011224 Cough Diseases 0.000 claims 3
- 102000002294 Purinergic P2X Receptors Human genes 0.000 claims 3
- 108010000836 Purinergic P2X Receptors Proteins 0.000 claims 3
- 230000004913 activation Effects 0.000 claims 3
- 238000002347 injection Methods 0.000 claims 3
- 239000007924 injection Substances 0.000 claims 3
- 238000001990 intravenous administration Methods 0.000 claims 3
- 230000009467 reduction Effects 0.000 claims 3
- 230000001515 vagal effect Effects 0.000 claims 3
- 210000001186 vagus nerve Anatomy 0.000 claims 3
- 206010006451 bronchitis Diseases 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 230000004044 response Effects 0.000 claims 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- WFTMQZSSJCKHNN-JZBGLOBFSA-N P(Cl)(Cl)(Cl)(Cl)Cl.[C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(N)=NC=NC12.[C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(N)=NC=NC12 Chemical compound P(Cl)(Cl)(Cl)(Cl)Cl.[C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(N)=NC=NC12.[C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(N)=NC=NC12 WFTMQZSSJCKHNN-JZBGLOBFSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 208000024716 acute asthma Diseases 0.000 claims 1
- UFZTZBNSLXELAL-IOSLPCCCSA-N adenosine 5'-[beta,gamma-methylene]triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)CP(O)(O)=O)[C@@H](O)[C@H]1O UFZTZBNSLXELAL-IOSLPCCCSA-N 0.000 claims 1
- 201000009267 bronchiectasis Diseases 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 238000002405 diagnostic procedure Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 239000000411 inducer Substances 0.000 claims 1
- 230000004941 influx Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000001640 nerve ending Anatomy 0.000 claims 1
- CAWZRIXWFRFUQB-IOSLPCCCSA-N α,β Methylene ATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)CP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O CAWZRIXWFRFUQB-IOSLPCCCSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59010104P | 2004-07-22 | 2004-07-22 | |
| US66203305P | 2005-03-15 | 2005-03-15 | |
| PCT/US2005/026884 WO2006012639A2 (en) | 2004-07-22 | 2005-07-22 | Method of diagnosing, monitoring and treating pulmonary diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008507368A JP2008507368A (ja) | 2008-03-13 |
| JP2008507368A5 true JP2008507368A5 (enExample) | 2008-08-14 |
Family
ID=35786780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007522850A Pending JP2008507368A (ja) | 2004-07-22 | 2005-07-22 | 肺疾患を診断、モニタリングおよび治療するための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20060029548A1 (enExample) |
| EP (1) | EP1773405A4 (enExample) |
| JP (1) | JP2008507368A (enExample) |
| AU (1) | AU2005266887B2 (enExample) |
| CA (1) | CA2573565A1 (enExample) |
| WO (1) | WO2006012639A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2620034C (en) * | 2005-09-01 | 2013-10-01 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| US9402633B2 (en) | 2006-03-13 | 2016-08-02 | Pneumrx, Inc. | Torque alleviating intra-airway lung volume reduction compressive implant structures |
| US8157837B2 (en) | 2006-03-13 | 2012-04-17 | Pneumrx, Inc. | Minimally invasive lung volume reduction device and method |
| US8888800B2 (en) | 2006-03-13 | 2014-11-18 | Pneumrx, Inc. | Lung volume reduction devices, methods, and systems |
| US8632605B2 (en) | 2008-09-12 | 2014-01-21 | Pneumrx, Inc. | Elongated lung volume reduction devices, methods, and systems |
| KR101422901B1 (ko) | 2009-02-13 | 2014-07-23 | 시오노기 앤드 컴파니, 리미티드 | 신규 트라이아진 유도체 및 그것을 함유하는 의약 조성물 |
| US20100222294A1 (en) * | 2009-02-27 | 2010-09-02 | Duska Scientific Co. | Formulations of ATP and Analogs of ATP |
| EP2432422A4 (en) | 2009-05-18 | 2018-01-17 | PneumRx, Inc. | Cross-sectional modification during deployment of an elongate lung volume reduction device |
| US20130164386A1 (en) * | 2010-06-17 | 2013-06-27 | The Johns Hopkins University | Targeting the Alpha3 Subnit of Na+-K+-ATPase for the Treatment of Cough with Sulfenamides |
| EP2604595B1 (en) | 2010-08-10 | 2016-03-16 | Shionogi&Co., Ltd. | Triazine derivative and pharmaceutical compound that contains same and exhibits analgesic activity |
| JP6138044B2 (ja) * | 2011-08-10 | 2017-05-31 | 国立大学法人富山大学 | 痺れ又は自発痛の評価方法及び薬物のスクリーニング方法 |
| US9550763B2 (en) | 2012-02-09 | 2017-01-24 | Shionogi & Co., Ltd. | Heterocyclic ring and carbocyclic derivative |
| TWI637949B (zh) | 2013-06-14 | 2018-10-11 | 塩野義製藥股份有限公司 | 胺基三衍生物及含有其等之醫藥組合物 |
| JP6546592B2 (ja) * | 2013-08-23 | 2019-07-17 | アファレント ファーマシューティカルズ インコーポレイテッド | 急性、亜急性または慢性の咳を治療するためのジアミノピリミジンｐ２ｘ３およびｐ２ｘ２／３受容体モジュレーター |
| WO2015061790A2 (en) | 2013-10-25 | 2015-04-30 | Pneumrx, Inc. | Genetically-associated chronic obstructive pulmonary disease treatment |
| US10390838B1 (en) | 2014-08-20 | 2019-08-27 | Pneumrx, Inc. | Tuned strength chronic obstructive pulmonary disease treatment |
| US11622716B2 (en) | 2017-02-13 | 2023-04-11 | Health Care Originals, Inc. | Wearable physiological monitoring systems and methods |
| US11272864B2 (en) | 2015-09-14 | 2022-03-15 | Health Care Originals, Inc. | Respiratory disease monitoring wearable apparatus |
| HUE061764T2 (hu) | 2015-09-29 | 2023-08-28 | Afferent Pharmaceuticals Inc | Diaminopirimidin-P2X3 és P2X2/3 receptor modulátorok felhasználásra köhögés kezelésében |
| US11241579B2 (en) * | 2016-04-22 | 2022-02-08 | The Regents Of The University Of California | Monitoring and modulation of parasympathetic nervous system |
| US10955269B2 (en) | 2016-05-20 | 2021-03-23 | Health Care Originals, Inc. | Wearable apparatus |
| US20210278418A1 (en) * | 2018-03-15 | 2021-09-09 | The Chidlren's Medical Center Corporation | Method for treating asthma or allergic disease |
| PL3862000T3 (pl) | 2018-10-05 | 2024-03-18 | Shionogi & Co., Ltd | Lek na przewlekły kaszel |
| MX2022002941A (es) | 2019-09-19 | 2022-04-06 | Shionogi & Co | Cristal de derivado de 1,3,5-triazina o solvato del mismo y metodo para producir el mismo. |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5122466A (en) * | 1989-06-13 | 1992-06-16 | North Carolina State University | Ballistic transformation of conifers |
| JP3121827B2 (ja) * | 1990-09-04 | 2001-01-09 | メドコ・リサーチ・インコーポレイテッド | アデノシンまたはそのリン酸化誘導体を活性成分とする気管支収縮性肺疾患の診断剤 |
| GB9109063D0 (en) * | 1991-04-26 | 1991-06-12 | Ici Plc | Modification of lignin synthesis in plants |
| US5527586A (en) * | 1992-03-18 | 1996-06-18 | Printron, Inc. | Apparatus and method for depositing metal particles on a dielectric substrate |
| US5348616A (en) * | 1993-05-03 | 1994-09-20 | Motorola, Inc. | Method for patterning a mold |
| FR2709666B1 (fr) * | 1993-09-07 | 1995-10-13 | Oreal | Composition cosmétique ou dermatologique constituée d'une émulsion huile dans eau à base de globules huileux pourvus d'un enrobage cristal liquide lamellaire. |
| EP0760850A1 (en) * | 1994-05-27 | 1997-03-12 | Glaxo Group Limited | P2x RECEPTORS (PURINOCEPTOR FAMILY) |
| US5597613A (en) * | 1994-12-30 | 1997-01-28 | Honeywell Inc. | Scale-up process for replicating large area diffractive optical elements |
| US6309580B1 (en) * | 1995-11-15 | 2001-10-30 | Regents Of The University Of Minnesota | Release surfaces, particularly for use in nanoimprint lithography |
| US6482742B1 (en) * | 2000-07-18 | 2002-11-19 | Stephen Y. Chou | Fluid pressure imprint lithography |
| US5874420A (en) * | 1995-12-26 | 1999-02-23 | Allegheny University Of The Health Sciences | Process for regulating vagal tone |
| US6204434B1 (en) * | 1996-09-11 | 2001-03-20 | Genesis Research & Development Corporation Limited | Materials and methods for the modification of plant lignin content |
| US6653528B1 (en) * | 1996-09-11 | 2003-11-25 | Genesis Research & Development Corporation Limited | Pinus radiata nucleic acids encoding O-methyl transferase and methods for the modification of plant lignin content therewith |
| US6410718B1 (en) * | 1996-09-11 | 2002-06-25 | Genesis Research & Development Corporation Ltd. | Materials and methods for the modification of plant lignin content |
| US5850020A (en) * | 1996-09-11 | 1998-12-15 | Genesis Research & Development Corporation, Ltd. | Materials and method for the modification of plant lignin content |
| US5735985A (en) * | 1996-11-15 | 1998-04-07 | Eastman Kodak Company | Method for micromolding ceramic structures |
| JP2001518118A (ja) * | 1997-03-25 | 2001-10-09 | アレゲニー ユニバーシティー オブ ザ ヘルス サイエンシズ | ヒト肥満細胞活性化のモジュレーション |
| US6225143B1 (en) * | 1998-06-03 | 2001-05-01 | Lsi Logic Corporation | Flip-chip integrated circuit routing to I/O devices |
| US6110401A (en) * | 1998-08-24 | 2000-08-29 | Physical Optics Corporation | Method and apparatus for replicating light shaping surface structures on a rigid substrate |
| US6190929B1 (en) * | 1999-07-23 | 2001-02-20 | Micron Technology, Inc. | Methods of forming semiconductor devices and methods of forming field emission displays |
| US6517995B1 (en) * | 1999-09-14 | 2003-02-11 | Massachusetts Institute Of Technology | Fabrication of finely featured devices by liquid embossing |
| DE60127098T2 (de) * | 2000-01-31 | 2007-11-29 | Genaera Corp. | Inhibitoren der mucin-synthese |
| US6387787B1 (en) * | 2001-03-02 | 2002-05-14 | Motorola, Inc. | Lithographic template and method of formation and use |
| DE60206164T2 (de) * | 2001-05-18 | 2006-06-22 | Abbott Laboratories, Abbott Park | Trisubstituierte-n-((1s)-1,2,3,4-tetrahydro-1-naphthalenyl) benzamide welche p2x3 und p2x2/3 enthaltende rezeptoren inhibieren |
| US6716754B2 (en) * | 2002-03-12 | 2004-04-06 | Micron Technology, Inc. | Methods of forming patterns and molds for semiconductor constructions |
-
2005
- 2005-07-22 JP JP2007522850A patent/JP2008507368A/ja active Pending
- 2005-07-22 AU AU2005266887A patent/AU2005266887B2/en not_active Ceased
- 2005-07-22 EP EP05776504A patent/EP1773405A4/en not_active Withdrawn
- 2005-07-22 WO PCT/US2005/026884 patent/WO2006012639A2/en not_active Ceased
- 2005-07-22 CA CA002573565A patent/CA2573565A1/en not_active Abandoned
- 2005-07-22 US US11/187,753 patent/US20060029548A1/en not_active Abandoned
-
2010
- 2010-07-19 US US12/839,196 patent/US20100286274A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008507368A5 (enExample) | ||
| Gentry et al. | Chronic obstructive pulmonary disease: diagnosis and management | |
| Redington | Modulation of nitric oxide pathways: therapeutic potential in asthma and chronic obstructive pulmonary disease | |
| Rabec et al. | Respiratory complications of obesity | |
| JP2010518122A5 (enExample) | ||
| JP2008507368A (ja) | 肺疾患を診断、モニタリングおよび治療するための方法 | |
| Aziz et al. | The triad of sleep apnea, hypertension, and chronic kidney disease: a spectrum of common pathology | |
| WO2006014381A3 (en) | Use of thioflavin radiolabeled derivatives in amyloid imaging gor assessing anti-amyloid therapies | |
| WO2010068754A3 (en) | Methods and compositions for delivery of medicaments to the lungs | |
| Murphy et al. | Reversal (antagonism) of neuromuscular blockade | |
| US9855229B2 (en) | Treatment of respiratory disorders using ROR-gamma inhibitors | |
| Vocci et al. | Vaccines against nicotine: how effective are they likely to be in preventing smoking? | |
| Jooste et al. | Neuromuscular blocking agents' differential bronchoconstrictive potential in Guinea pig airways | |
| Kotsiou et al. | The role of nitric oxide in pleural disease | |
| WO2005046720A3 (en) | Diagnosis, prognosis and treatment of pulmonary diseases using foxa2 | |
| Albertson et al. | The pharmacological approach to the elderly COPD patient | |
| JP3384539B2 (ja) | 喘息治療剤 | |
| Lee et al. | The effect-site concentration of propofol producing respiratory depression during spinal anesthesia | |
| EA200701077A1 (ru) | Применение конъюгатов липидов при лечении заболеваний | |
| Daabiss et al. | Effects of lornoxicam on the hemodynamic and catecholamine response to laryngoscopy and tracheal intubation | |
| Volta et al. | Respiratory function after aortic aneurysm repair: a comparison between retroperitoneal and transperitoneal approaches | |
| Mieszczański et al. | Successful Anesthetic Management for Obese Patients with Interstitial Lung Disease Undergoing Laparoscopic Sleeve Gastrectomy: A Bridge to Improved Lung Transplant Eligibility | |
| JP2009501707A5 (enExample) | ||
| Rice et al. | Tachykinin‐induced bronchoconstriction in sheep is NK‐1 receptor mediated and exhibits tachyphylaxis | |
| JP2006101872A (ja) | 薬効評価用動物、薬効評価用動物の喘息発症方法及びその動物を用いた薬効評価方法 |